OTCBB:RZLT
Rezolute, Inc. Stock News
$3.87
-0.390 (-9.15%)
At Close: Jun 25, 2024
Rezolute Announces Promotion of Brian Roberts, M.D. to Chief Medical Officer
11:00am, Wednesday, 01'st Jun 2022 GlobeNewswire Inc.
REDWOOD CITY, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential
Rezolute, Inc. Announces Closing of Registered Direct Offering
01:33pm, Wednesday, 04'th May 2022 GlobeNewswire Inc.
REDWOOD CITY, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential t
Rezolute, Inc. Announces Aggregate $130 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market
03:25am, Monday, 02'nd May 2022 GlobeNewswire Inc.
REDWOOD CITY, Calif., May 01, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential t
Rezolute Announces Positive Data from its Phase 2b (RIZE) Study of RZ358 in Patients with Congenital Hyperinsulinism
06:00pm, Sunday, 01'st May 2022 GlobeNewswire Inc.
Results Presented Today at the Pediatric Endocrine Society’s 2022 Annual Meeting Results Presented Today at the Pediatric Endocrine Society’s 2022 Annual Meeting
Rezolute Joins the Rare Disease Company Coalition
11:00am, Tuesday, 29'th Mar 2022 GlobeNewswire Inc.
Rezolute joins group aimed at helping advance timely access to life-saving therapies for those impacted by rare diseases Rezolute joins group aimed at helping advance timely access to life-saving ther
Rezolute (RZLT) Posts Positive Data From Congenital HI Study
06:02pm, Thursday, 24'th Mar 2022 Zacks Investment Research
Rezolute (RZLT) releases favorable data from the phase IIb RIZE study on its lead candidate RZ358, currently being investigated for congenital hyperinsulinism.
Rezolute (RZLT) Posts Positive Data From Congenital HI Study
03:03pm, Thursday, 24'th Mar 2022
Rezolute (RZLT) releases favorable data from the phase IIb RIZE study on its lead candidate RZ358, currently being investigated for congenital hyperinsulinism.
Rezolute Announces Positive Results from the Phase 2b RIZE Study of RZ358 in Congenital Hyperinsulinism
11:00am, Wednesday, 23'rd Mar 2022 GlobeNewswire Inc.
The RIZE study demonstrated highly significant improvements in hypoglycemia and good safety and tolerability
Rezolute Highlights Early-Stage Study Results For RZ402 In Diabetic Macular Edema
03:24pm, Tuesday, 22'nd Feb 2022 Benzinga
Rezolute Inc (NASDAQ: RZLT ) announced topline data from its Phase 1b multiple-ascending dose (MAD) study of RZ402, a plasma kallikrein inhibitor (PKI) for diabetic macular edema (DME). Results of the MAD study further validate and support the potential for once-daily oral Full story available on Benzinga.com
Rezolute Announces Positive Study Results for RZ402, an oral PKI being developed for DME
12:00pm, Tuesday, 22'nd Feb 2022 GlobeNewswire Inc.
Phase 2 proof-of-concept study anticipated in 2H 2022 Phase 2 proof-of-concept study anticipated in 2H 2022
Rezolute GAAP EPS of -$0.80
09:57pm, Wednesday, 09'th Feb 2022 Seeking Alpha
Rezolute press release (RZLT): Q2 GAAP EPS of -$0.80.Cash and cash equivalents of $77.4M.“We have maintained excellent momentum and are on track to report topline data before the end…
Rezolute Reports Second Quarter Fiscal 2022 Financial Results and Highlights Company Progress
09:05pm, Wednesday, 09'th Feb 2022 GlobeNewswire Inc.
Topline results from RZ358 Phase 2b and RZ402 Phase 1b studies expected before the end of Q1 2022 Topline results from RZ358 Phase 2b and RZ402 Phase 1b studies expected before the end of Q1 2022
Rezolute, Inc. (NASDAQ:RZLT) Receives $20.40 Average PT from Analysts
10:28pm, Sunday, 19'th Dec 2021 Dakota Financial News
Shares of Rezolute, Inc. (NASDAQ:RZLT) have been assigned an average rating of Buy from the six research firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average twelve-month price objective among brokerages that []
Rezolute (NASDAQ:RZLT) Given New $17.00 Price Target at Canaccord Genuity
12:16pm, Monday, 29'th Nov 2021 Transcript Daily
Rezolute (NASDAQ:RZLT) had its price objective lowered by Canaccord Genuity from $30.00 to $17.00 in a research report released on Monday morning, The Fly reports. Canaccord Genuity currently has a buy rating on the stock. A number of other equities analysts have also issued reports on RZLT. JMP Securities decreased their target price on shares []
Rezolute, Inc. (NASDAQ:RZLT) Receives Consensus Recommendation of Buy from Analysts
12:38am, Thursday, 25'th Nov 2021 Dakota Financial News
Shares of Rezolute, Inc. (NASDAQ:RZLT) have earned an average recommendation of Buy from the six research firms that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average twelve-month price target among analysts that have []